Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.

© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.

Stock Quote Disclaimer: Copyright © 1998-2002 MarketWatch.com Inc. User agreement applies. Historical and current end-of-day data provided by Interactive Data Corp. Intraday data is at least 20-minutes delayed. All times are EDT. Intraday data provided by S&P Comstock and subject to terms of use.

NYSE | BMY 21.75 | -1.04 | 11:31 AM EDT | 09 May 2008

Top Stories

Nordic Capital and
Avista Capital Partners
to Acquire ConvaTec
for Approximately $4.1 Billion
Read more >>

Uninsured and Need Help Paying for Your Bristol-Myers Squibb Cancer Medicine?
A new website launched this month helps cancer patients who cannot afford their Bristol-Myers Squibb medicine. Read more >>

Latest News
05.08.2008>>ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged 10-17) With Manic and Mixed Episodes of Bipolar I Disorder and Adolescents (Aged 13-17) With Schizophrenia 05.08.2008>>U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in the Acute Treatment of Adults With Manic and Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features 05.07.2008>>Bristol-Myers Squibb to Present at Healthcare Conference